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ABSTRACT 
 
Background: 
RTS,S candidate malaria vaccine has been shown to be highly immunogenic in children 
and infants, but the  protective immune mechanisms still remain to be clearly elucidated. It 
is believed that RTS,S elicits a strong neutralizing humoral immune response directed 
against surface-exposed sporozoite proteins and cell mediated immune (CMI) responses 
characterized by predominantly CD4+ Th1 cells. The objective of this study was to 
investigate humoral and cell-mediated immune responses to the RTS,S/AS02D malaria 
vaccine and its association with protection against infection and disease by P. falciparum. 
  
Methodology and Principal Findings:  
This secondary data analysis from data of a phase I/IIb randomized, double-blind, 
controlled trial, included 154 healthy infants living in rural Mozambique, previously 
immunized with  RTS,S/AS02D candidate malaria vaccine or the control Engerix-B™ 
vaccine. 
 Antibodies against circumsporozoite protein (CSP) and hepatitis-B surface antigen 
(HBsAg) were measured with a standard ELISA. Fresh blood intracellular staining assay 
was performed to evaluate the expression of IL-2 and IFN-γ by CD4+ and CD8+ cells in 
response to in vitro stimulation of specific peptides. Data was evaluated for association 
with the risk of malaria detected by both active and passive case detection of infection over 
a period of 6 months post dose 3.  
Anti-HBs antibody geometric mean titers declined from 10,082 mIU/mL one month post 
Dose 3 to 2,751 mIU/mL at 12 months post Dose 3 in the RTS,S/AS02D group; anti-HBs 
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geometric mean titers were 392.4 mIU/mL and 263.9 mIU/mL, respectively in the Engerix-
BTM group. Anti-CSP antibody geometric mean titers declined from 199.9 EU/mL one 
month post Dose 3 to 7.3 EU/mL at 12 months post Dose 3 in the RTS,S/AS02D group. 
Median stimulation indices of HBs-specific IL-2 and IFN-γ producing CD8+ T cells was 
higher in the RTS,S/AS02D group than in control group (Wilcoxon rank sum p-values for 
IFN-γ = 0.015, for IL-2 = 0.030) at 10.5 weeks post immunization.  Median stimulation 
indices of anti-CSP specific IFN-γ producing CD8+ T cells at the same time point was 
1.13 (IQR: 0.79 - 1.67; p=0.029).  For specific IL-2-producing CD4+ T cells, the median 
SI was 1.14 (IQR: 0.74 – 1.60, p=0.043) at 10.5 weeks post dose three.  
 
The reduction in hazards of malaria infection were 18.3 % (95% CI: -267.9 – 81.8, 
p=0.793) and -12.0 % (95% CI: -295 – 68.2, p=0.86) for specific IL-2  CD4+ stimulation 
indices;  For specific CD8+ IFN-γ stimulation indices  the hazards were -103.6% (95% 
CI: -690.9 – 47.6; p=0.305) and 48.8% (95% CI: -97.0 – 86.7; p=0.33)  at four and 10.5 
weeks post immunization respectively. 
 
Conclusion: 
 
The RTS,S/AS02D vaccine was immunogenic and has elicited detectable levels of CSP-
specific cell mediated responses. No evidence of association was found between the   
antibodies anti-CSP and specific cell-mediated responses and the risk of malaria. 
 
 
 
vi 
 
 
 
 
ACKNOWLEDGMENTS 
 
Special thanks to my supervisor, Prof. Martin Grobusch for his continuous support and 
guidance throughout this research. This work would not be possible without his help. 
I thank Dr. John Aponte who guided me and reviewed the statistical analysis and helped me 
during the hard moments. 
I thank Dr Pedro Alonso and the all CISM research team for their encouragement and 
support to my studies.  
To all my relatives and friends, thank you very much for being such hard enthusiasts of my 
studies.  
To all my Lecturers and staff at the Wits School of Public Health, thanks a lot to let me 
know how important is to be committed to save lives through research and knowledge. 
Finally, I thank my lovely wife Ercília, source of my inspiration.  
 
 
 
 
 
 
 
 
 
vii 
 
 
 
 
 
 
PUBLICATIONS 
 
Some of the data presented in this research report have been included in the following 
publication: 
 
Aponte, J.J., Aide, P., et al., Safety of the RTS,S/AS02D candidate malaria vaccine in 
infants living in a highly endemic area of Mozambique: a double blind randomised 
controlled phase I/IIb trial. Lancet, 2007. 370(9598): p. 1543-51. 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
CONTENTS 
 
DECLARATION ........................................................................................................................ ii 
ABSTRACT ............................................................................................................................... iv 
ACKNOWLEDGMENTS ......................................................................................................... vi 
PUBLICATIONS ...................................................................................................................... vii 
LIST OF FIGURES .................................................................................................................... x 
LIST OF TABLES ..................................................................................................................... xi 
NOMENCLATURE.................................................................................................................. xii 
 
CHAPTER ONE: INTRODUCTION ........................................................................................ 1 
1.1. Introduction .................................................................................................................. 1 
1.2. Literature review .......................................................................................................... 3 
1.3. Objectives ..................................................................................................................... 6 
CHAPTER TWO: MATERIALS AND METHODS ............................................................... 7 
2.1.  Study Population .......................................................................................................... 7 
2.2. Study Design ................................................................................................................ 7 
2.3. Methodology .................................................................................................................... 8 
2.3.1. Information program ................................................................................................. 8 
2.3.2. Methods of data collection ....................................................................................... 8 
2.3.3. Laboratory tests ......................................................................................................... 8 
ix 
 
2.4. Data Processing and Statistical Methods ...................................................................... 10 
2.5. Ethical considerations .................................................................................................... 11 
CHAPTER THREE: RESULTS .............................................................................................. 12 
CHAPTER FOUR: DISCUSSION .......................................................................................... 23 
CHAPTER FIVE: CONCLUSIONS AND RECOMMENDATIONS .................................. 26 
REFERENCES .......................................................................................................................... 27 
APPENDIX ............................................................................................................................... 30 
 
                                                                                                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
 
 
 
 
 
 
 
LIST OF FIGURES 
 
Figure 1: Reverse cumulative distribution of Anti-CSP and Anti-HBs 
Geometric Means Titers (GMTs) antibodies 
 
Figure 2:  Association between anti-CSP specific-cytokine responses and 
antibodies against CSP  
 
 
 
 
 
 
 
 
 
 
 
xi 
 
 
 
 
 
 
 
LIST OF TABLES 
 
Table 1:  Baseline characteristics of participants prior to immunization 
Table 2:  Seroprotective rates and GMTs for anti-CSP and anti-HBs antibodies titers 
Table 3:  Comparison of anti-CSP specific IFN-γ and IL-2 CD4+ and CD8+ responses 
between participants receiving RTS,S/AS02D or Engerix-B™  vaccines 
Table 4:  Comparison anti-HBs specific IFN-γ and IL-2 CD4+ and CD8+ responses 
between participants receiving RTS,S/AS02D or Engerix-B™  vaccines 
Table 5:  Association between antibodies anti-CSP and specific IFN-γ and IL-2 CD4+ 
and CD8+ response 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
NOMENCLATURE 
 
ADI:  Active Detection of Infection 
anti-CS:  antibody to the P. falciparum circumsporozoite (CS) repeat protein 
anti-HBsAg:  antibody to the hepatitis B surface antigen 
CISM:  Centro de Investigação em Saúde de Manhiça, Moçambique. 
CMI:  Cell-mediated immunity 
CSP: Circumsporozoite protein 
DTPw/Hib:  Diphtheria, tetanus, whole-cell pertussis and Haemophilus influenzae type B 
vaccine (TETRAacHib) 
ELISA:  Enzyme Linked Immunosorbent Assay 
EPI:  Expanded Programme on Immunization 
GMT:  Geometric mean titer 
GSK:  GlaxoSmithKline 
HBsAg:  Hepatitis B surface antigen 
Hib:  Haemophilus influenzae type B 
HIV:  Human immunodeficiency virus 
ICS: Intracellular cytokine staining  
ICH/GCP:  International Conference of Harmonization/ Good Clinical Practices  
IFN-Interferon gamma 
IL-2: Interleukin 2  
TNF-: Tumoral necrosis factor alfa 
TRAP: Thrombospondin-Related Adhesion Protein 
MPL:  3-deacylated monophosphoryl lipid A 
xiii 
 
MSP: Merozoite Surface Protein  
MVI:  Malaria Vaccine Initiative 
P. falciparum:  Plasmodium falciparum 
PATH:  Program for Appropriate Technology in Health 
PCD: Passive Detection of Infection 
PBMC: Peripheral blood mononuclear cells 
QS 21:  ‘Quillaja saponaria 21’: a triterpene glycoside purified from the bark of Quillaja 
saponaria 
RF1:  A protective epitope against HBsAg 
RESA: Ring-infected Erythrocyte Surface Antigen 
RTS:  Hybrid protein comprising S (hepatitis B surface antigen) and CSP portions 
RTS,S:  Particulate antigen, containing both RTS and S (hepatitis B surface antigen) 
proteins 
S: Surface antigen of hepatitis B virus (HBsAg) 
SI: Stimulation indice 
 
 
 
 
 
 
 
1 
 
CHAPTER ONE: INTRODUCTION 
1.1. Introduction 
Malaria caused by the parasite Plasmodium falciparum is responsible for approximately 1 
million children deaths every year, mainly in sub-Saharan Africa, and is the most common 
reason for hospital admission. Every year there are around 250 million malaria clinical 
episodes in children under five years [1]. Various reasons account for the increase in 
incidence of malaria in much of Africa during the 1980’s and 1990’s; amongst others, the 
emerging resistance to conventional antimalaria drugs such as chloroquine and insecticide 
resistance of the anopheline vectors.  
In recent years, increased efforts of malaria control that include long lasting insecticide 
treated nets (LLINs) and new first line treatments of malaria with more effective 
combinations, is leading to a reduction in malaria morbidity which yet has to be fully 
documented [1]. However in some areas particularly in regions where there is ongoing 
intensive malaria research it is estimated that the overall numbers of cases of clinical 
malaria will more than double over the next 20 years without effective control [2]. 
Hepatitis B is an infection of the liver due to hepatitis B virus (HBV) and is an important 
public health problem across the developing world. World-wide, approximately 350 million 
people carry HBV, and about 1 million chronically ill die annually [3]. The likelihood of 
the infection becoming chronic depends largely on the age at infection: 90% if infected in 
infancy, 30% to 50% if infected between the ages of 1 to 4 years, and low in adulthood. For 
those that become chronically infected during childhood, the risk of death from HBV-
related liver cancer or cirrhosis in adult life is approximately 25% [4]. 
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The RTS,S/AS02 candidate malaria and hepatitis B vaccine consists of sequences of the 
circumsporozoite protein (CSP) and hepatitis B surface antigen (HBsAg) with the adjuvant 
AS02D (proprietary oil-in-water emulsion, MPL® and QS21 immunostimulants).  
The RTS,S vaccine with the AS0 family of adjuvant is being developed for the routine 
immunization of infants living in malaria-endemic areas and would offer protection against 
both malaria and hepatitis B. 
A vaccine that induces partial immunity against pre-erythrocytic stages of malaria disease 
may provide protection to vulnerable young children from the severe forms of the disease, 
whilst continuing exposure allows them to build up natural immunity. Acquisition of 
natural immunity may be important to prevent a shift of severe disease burden to older age 
groups upon waning of vaccine-induced immunity [5]. 
Previous studies have demonstrated that RTS,S/AS02 vaccine is a powerful inducer of 
antigen-specific humoral and cell mediated immunity (CMI) [6-9]. The RTS,S/AS02A 
vaccine is believed to elicit a strong neutralizing humoral immune response directed against 
surface-exposed sporozoite proteins and elicit CMI responses characterized by 
predominantly CD4+  Th1 cells, that are hypothesized to either destroy infected hepatocytes 
and/or limit intracellular parasite development through appropriate cytokines. Th1 
cytokines such as IFN-, TNF- and IL-2 have been described to be produced after 
stimulation with RTS,S or peptides derived from the circumsporozoite protein [10]. It is 
unclear whether CD8+ cells play a role in protective immunity, thus this remains to be 
elucidated. 
Antigen-specific humoral and cell mediated immunity induced by a vaccine antigen 
formulated in AS02 adjuvant has never before been measured in infants. As it is believed to 
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be a key component in protecting vaccinees agains the P. falciparum parasite, it has been 
measured in a trial with Mozambican infants [11] and was further analyzed (as secondary 
data) in this study.  
1.2. Literature review 
The GlaxoSmithKline (GSK) Biologicals candidate vaccine against P. falciparum, the 
RTS,S/AS02A malaria vaccine, has been shown to be safe and immunogenic in malaria-
experienced adult populations in The Gambia and Kenya and malaria-naive adult 
populations in Belgium and the USA [6-8]. According to Kester et al. (2001), the vaccine 
has been shown to protect between 42% and 86% of healthy non-immune volunteers 
against infection in homologous sporozoite challenge studies, when given according to a 2 
or 3 dose vaccination schedule [12]. In addition, a prolongation of the pre-patent period 
was observed in the majority of non-protected volunteers [12]. 
Subsequently RTS,S/AS02A studies were done in children aged 6 to 11 years in The 
Gambia, and demonstrated the safety of the vaccine in this age group as well as its highly 
immunogenic profile with regard to the mounting of anti-CSP and anti-HBs antibodies 
[13]. 
Overall, the GMT values observed in this population of children aged 6 to 11 years were 
within the ranges seen in previous studies with the RTS,S/AS02A vaccine in malaria-naïve 
adult subjects [12]. 
Subsequent to these studies, three sequential double-blind randomized controlled trial of 
the RTS,S/AS02A administered according to a 0, 1 and 2 months schedule were conducted 
in Mozambique [5, 14, 15]. In all these studies the vaccine proved to be safe and well 
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tolerated, with an acceptable reactogenicity profile, and inducing significant humoral 
immune responses against both CSP and HBsAg epitopes [5, 14, 15]. The non-inferiority of 
the HBsAg response of RTS,S/AS02A compared to the licensed vaccine Engerix-B™  
(GSK Biologicals, Belgium) was also demonstrated by Macete et al [15]. The vaccine 
efficacy for the first malaria clinical episode was 29.9% (95% CI 11 – 44.8; p=0.004) and 
the prevalence of P. falciparum infection was 37% lower in the RTS,S/AS02A group 
compared with the control group at the end of a six-month observation period in 
Mozambican children aged 1 to 4 years [5]. 
The first administration of the RTS,S/AS02D to infants was carried out in Mozambique  
and showed that the vaccine was safe and immunogenic. The study showed a 65.9% (95% 
CI: 42.6 - 79.8, p <0.0001) delay in time to new infection over a 3.5 month period [11].  
A recent trial of the same vaccine carried out in Tanzanian infants showed no interference 
with the immunologic response to WHO’s Expanded Programme on Immunization (EPI) 
vaccines and a 65.2% reduction in malaria infection incidence [16]. Another trial in 
children 5 to 17 months old with the adjuvant AS01 in Tanzania and Kenya demonstrated a 
53% (95% CI 28 – 69, p<0.001) reduction in clinical malaria [17]. These estimates of 
vaccine efficacy are remarkably consistent with previous data from Mozambique. 
There is evidence and proof of concept efficacy in preventing infection, clinical malaria and 
severe malaria [5, 11]. However, there is still a lack of understanding of the types of 
immune responses needed for protection [18]. 
By now, the RTS,S is the most advanced pre-erythrocytic vaccine candidate in 
development. Other similar vaccines, based on CSP, thrombospondin-related adhesion 
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protein (TRAP) and other liver stage antigens,  have been evaluated in clinical trials, with 
initial encouraging results [19, 20].   
Several Phase III trials of the SPf66 vaccine candidate, a synthetic multiepitope, multistage 
peptide vaccine have reported low efficacy results and halted its development [21].  
Blood-stage (erythtocytic) vaccines aim to stimulate immune response against surface 
proteins of merozoites, reducing incidence and severity of clinical disease. One of these 
vaccine candidates, with the Plasmodium falciparum merozoite surface protein 3 (MSP3) 
antigen has been shown to induce cellular and humoral immune responses [22].  In a phase 
2 clinical trial of a combined vaccine containing the antigens MSP1, MSP2 and ring-
infected erythrocyte surface antigen (RESA) in Papua New Guinea,  the authors found that 
the vaccine reduced the parasite density by 62 % (95% CI: 13% – 84%) in children not 
pretreated with antimalarial drugs [23].  In a phase Ib dose-escalating trial among 
Tanzanian children aged 12 to 24 months, a blood stage malaria vaccine candidate MSP3 
adjuvanted by aluminium hydroxide has been shown to elicit strong cytophilic IgG 
responses (subclasses IgG 1 and 3), both recognized in the parasite-killing mechanisms by 
monocytes [24]. 
 
Other interesting approaches are the transmission-blocking vaccines. These are designed to 
break the chain of transmission by inducing antibodies in the human host that inhibit 
parasite development in the salivary glands of mosquitoes preventing the development of 
infectious sporozoites [25]. 
Despite promising, further research and development still needed for these candidates, 
vaccine before proceeding for phase 3 trials. 
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1.3. Objectives 
The main objective of this study was to assess the humoral and cell-mediated immune 
responses to the RTS,S/AS02D malaria vaccine in infants, and its association with 
protection against infection and disease by P. falciparum, and specifically: 
- To describe the levels of antibodies against CSP antigens in infants prior to vaccination, 
four weeks, 10.5 weeks and 12 months after the third dose of RTS,S/AS02D or 
Engerix-B™; 
- To describe the levels of antibodies against HBs antigens in infants prior to 
immunization, four weeks and 12 months after the third dose of RTS,S/AS02D or 
Engerix-B™; 
- To compare specific CD4+ and CD8+ cell mediate immune responses in infants 
immunized with RTS,S/AS02D against the response of infants immunized with 
Engerix-B™ prior to vaccination, at four and 10.5 weeks after the third dose; 
- To investigate the association between CMI (IFN- and IL-2) and CSP antibody 
responses in infants vaccinated with RTS,S/AS02D. 
-  To investigate the association between CMI (IFN- and IL-2) and the risk of infection or 
disease due to P. falciparum in infants vaccinated with RTS,S/AS02D. 
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CHAPTER TWO: MATERIALS AND METHODS 
2.1.  Study Population 
The study population comprised healthy male and female infants aged 6 to 12 weeks at 
enrollment living in Ilha Josina Machel and Taninga, two rural villages located in the 
Manhiça demographic surveillance site, Mozambique, from June 2005 to December 2007.  
 
2.2. Study Design 
This study constitutes a secondary data analysis from the Malaria-038 clinical trial carried 
out in Mozambique between June 2005 and December 2007, using information collected 
for immunogenicity and efficacy. The original study was a phase I/IIb randomized, double-
blind, controlled trial of the safety, immunogenicity and proof-of-concept of 
RTS,S/AS02D, a candidate malaria vaccine in infants living in a malaria-endemic region. 
Infants were randomized and immunized with either the RTS,S/AS02D or the control 
vaccine Engerix-B™ at 10, 14 and 18 weeks of age staggered with the EPI vaccines 
(TETRActHib) at 8, 12 and 16 weeks of age [11]. The study was registered with 
ClinicalTrials.gov identifier NCT00197028. 
 
Briefly, infants were screened between 6 and 12 weeks of age after an informed consent 
was obtained from parents or guardians. At the first EPI vaccination visit, they were 
randomly distributed in two immunization groups to receive either the RTS,S/AS02D or 
the hepatitis B Engerix-B™  (GSK Biologicals, Belgium) study vaccines. All 
immunizations were given intramuscularly.  
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The study included all participants with available data for immunogenicity endpoints 
(received the three immunization doses, had available samples processed and complete 
follow up data). Those children who had received immunoglobulins and/or any blood 
product, chronic immunosuppressants (more than 14 days) or other immune-modifying 
therapy were excluded from the study. 
Infants at high risk of vertical transmission of hepatitis B infection were excluded from the 
study because it used an experimental hepatitis B vaccine. A licensed hepatitis B vaccine in 
a schedule beginning at birth was offered to these infants.  
Infants of HIV-positive women were excluded to avoid confounding the safety pattern 
associated with the investigational vaccine.  
2.3. Methodology 
2.3.1. Information program 
Prior to study start, a community information program informed the local population of the 
study. Throughout the period of enrollment, study information was presented at antenatal 
clinics to expectant mothers.  
2.3.2. Methods of data collection 
Information related to all study visits and procedures was collected using a conventional 
case report form (CRF).   
2.3.3. Laboratory tests   
Blood samples for immunogenicity were drawn from children prior to first immunization 
(screening) and then at 4 and 10.5 weeks after the third immunization with RTS,S/AS02D 
or Engerix-B™. 
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Cases of malaria infection by P. falciparum were monitored by active detection of infection 
(ADI) commencing 2 weeks after dose 3 and performed every-other two weeks for 12 
weeks. Blood slides for parasitaemia determination were collected and axillary temperature 
recorded irrespective of symptoms. In all children, parasitaemia was presumptively cleared 
with amodiaquine plus sulfadoxine and pyrimethamine 2 weeks before the final dose of 
RTS,S/AS02D or Hepatitis-B vaccine. Only children without parasitaemia started the 
active detection of infection. Children found positive for P. falciparum infection were 
treated with the first line treatment and excluded from further assessment of active 
detection of infection. Re-infections were assessed by passive case detection (PCD). 
PCD was performed through monitoring of all attendances to health facilities and 
ascertainment of episodes of clinical malaria including blood smear for infants with 
documented fever (temperature equal or superior to 37.5°C) or history of fever in the 
preceding 24 hours. This method was also used to follow-up cases of re-infections by P. 
falciparum. 
Antibodies against the CS repeat region were measured by a standard ELISA using plate 
absorbed with recombinant R32LR with an assay cut-off of 0.5 EU/mL. Anti-HBsAg 
antibody levels were measured using a commercial radioimmunoassay (AUSAB, Abbott, 
IL, USA) with an assay cut-off of 10 IU/mL.  
Fresh whole blood intracellular staining was done to evaluate the expression of IL-2 and 
IFN-gamma by CD4+ and CD8+ T cells in response to in vitro stimulation with peptide 
pools of either CSP or HBsAg. After the stimulation, erythrocyte lysis was performed using 
1X FACS lysing solution (BD Biosciences) at a room temperature during 10 minutes. 
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Fluorochrome-conjugated antibodies to the surface markers [(anti-CD8+/APC, anti-
CD4+/FITC and anti-CD3/PerCP (BD, PharMingen)] were used to stain the cells. Then the 
cells were fixed and permeabilized with a solution containing paraformaldehyde  and 
saponin (Cytofix/Cytoperm, BD Biosciences) for 20 min on ice/darkness, split into two 
tubes and stained with PE-conjugated anti-IFN- or anti-IL-2 antibodies (BD, 
FastImmune). Stimulation indexes were calculated as ratios between the proportions of 
peptide-specific cells over proportion of control stimulated cells (denominator).   
 
2.4. Data Processing and Statistical Methods 
 
The original dataset was cleaned and verified for completion/missing data using the study 
number as the identifier key. The variables of interest were extracted and analyzed using 
STATA® (College Station, Texas, USA) version 10.   
The Geometric Mean Titers (GMTs) calculations were calculated by taking the anti-log of 
the mean of the log10 titer transformations. Antibody titers below the cut-off of the assay 
were given an arbitrary value of half the cut-off for the purpose of GMT calculation agreed 
by the investigators previously to unblinding of the primary data. 
 
The seroprotective level for anti-HBs is ≥10 mIU/mL. The percentage of subjects with 
protective levels of anti-HBs (≥10 mIU/mL) with 95% confidence interval (95% CI) were 
determined at each blood sampling time point (screening, one  and 12 months after third 
dose).  
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The percentage of subjects with sero-positive levels of anti-CSP (proportion of subjects 
with anti-CSP antibody titers greater than or equal to 0.5 EU/mL ) with 95% CI were 
determined at screening, one, 31/2 and 12 months after third dose. 
The anti-HBs and anti-CSP antibody titers were summarized by GMTs with 95% CI at all 
time points at which serological samples were taken.  Reverse cumulative distribution plots 
were used for visual assessment of distributions of the antibody titers and a Wilcoxon rank 
sum test was used to evaluate if the distribution were similar. 
 
The proportion of responders in each group was compared using a chi squared test. 
Differences between both vaccine groups in intracellular median stimulation indexes and 
were assessed using the Wilcoxon rank sum test.  
The association between specific anti-CSP immune responses (IFN- and IL-2 for both 
CD4+/CD8+ responses) and the risk of malaria was done using Cox regression models. Data 
on malaria incidence was derived from the primary efficacy data [11].  
 
2.5. Ethical considerations 
The study protocol was approved by the Wits Ethics Committee on Human Research 
(ethics clearance in appendix A). The primary study was authorized by the Mozambican 
National Bioethics Committee, the Hospital Clinic of Barcelona Ethics Review Committee 
and the PATH Human Subjects Protection Committee and implemented according to the 
International Conference of Harmonization Good Clinical Practices (ICH/GCP) guidelines. 
GSK Biologicals (Rixensart, Belgium) monitored the study.  
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CHAPTER THREE: RESULTS  
 
A total of 154 participants were included in the immunogenicity cohort analysis, 75 in the 
RTS,S/AS02D group and 79 in the Engerix-B™  group. The proportion of missing data 
was similarly distributed between the two groups. Table 1 summarises the general 
characteristics of the participants.  Mean age at enrolment was 8.3 weeks in both groups. 
There were relatively more males than females in the RTS,S/AS02D group than in the 
control group. The opposite figure was observed in terms of female participants (more 
females in the control groups). The comparison groups had similar distribution in terms of 
weight and the main haematological indicators. 
 
Table 1: Baseline characteristics of infants prior to vaccination   
  
RTS,S/AS02D 
       (n=75) 
Engerix-BTM 
     (n=79) 
Age(weeks): mean (SD) 8.3 (1.4) 8.3 (1.0) 
Gender 
    Male 40 (53.3) 34 (43.0) 
Female 35 (46.7) 45 (57.0) 
Weight (Kg): mean (SD) 5.01 (0.6) 5.04 (0.6) 
Haemoglobin (mg/dl): mean (SD) 108.3 (11.1) 108.4 (12.8) 
Total WBC: median (IQR) 9.5 (8.0 - 11.2) 9.9 (8.5 - 11.6) 
SD= Standard Deviation; IQR=Inter Quartile Range; WBC= Whole Blood Count 
   
Table 2 shows the anti-HBs, anti-CS seroprotection rates and GMTs at screening, one and 
twelve months after the third dose of RTS,S/AS02D or Engerix-B™  vaccination. Prior to 
vaccination, the proportion of participants with seroprotective levels of anti-HBs antibodies 
was similar in both groups (36.1% (95% CI: 25.1% – 48.3%) and 41.4% (95% CI: 29.8% - 
53.8%) for RTS,S and Engerix-B™  respectively). Pre-vaccination anti-HBs GMTs were 
below 17 mIU/ml. 
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Anti-HBs GMTs had declined from 10082 mIU/ml (95% CI: 7495 – 13744) at one month 
post dose 3 to 2751 mIU/ml at 12 months post dose 3 in participants receiving 
RTS,S/AS02D. Anti-HBs GMTs were 392.4 mIU/ml (95% CI: 297 – 519) and 263.9 
mIU/mL, respectively, in the Engerix-B™ group.  
 
In terms of anti-CSP response at the screening, similar proportions of participants were 
seropositive in the comparison groups, with 31.6% (95% CI: 21.4% – 43.3%) in the 
RTS,S/AS02D and 33.8% (95% CI: 23.4% - 45.4%) in the Engerix-B™  group. The pre-
vaccination GMTs were below the assay cut-off (0.5 EU/mL).  
At one month post dose 3 of RTS,S/AS02D or Engerix-B, 98.6% of recipients of 
RTS,S/AS02D and 4.4% of recipients of Engerix-B™  were seropositive for anti-CSP 
GMTs. 
A marked increase in anti-CSP antibody GMTs was observed at one month post dose 3 of 
RTS,S/AS02D (199.9 EU/mL) while no increase was observed one month post dose 3 of 
Engerix-B™  (<0.5 EU/mL).  
At 10.5 weeks post dose 3 of RTS,S/AS02D, anti-CSP antibody GMTs had decreased to 
58.8 EU/mL; however, 98.1% of subjects were still seropositive for anti-CSP antibodies.  
 
At the end of the follow up period (12 months post dose 3), anti-CSP antibodies reached the 
lowest observed value (7.3 EU/mL) in the RTS,S/AS02D group. 
 At 10.5 weeks post dose 3 of Engerix-B™  , 19.7% of subjects were seropositive for anti-
CSP GMTs; anti-CS antibody GMTs were below the assay cut-off (<0.5 EU/mL).  
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Table 2: Seroprotective rates and GMTs for anti-CSP and anti-HBs antibodies titers 
                          
 
 RTS,S/AS02D  
 Engerix-BTM 
 
 Seropositive GMT (EU/ml)  
 Seropositive GMT (EU/ml) 
Antibodies N n % 95% CI value 95% CI  N N % 95% CI value 95% CI 
Anti-CSP               
Baseline 76 24 31.6 21.4 - 43.3 0.4 0.3 - 0.5  77 26 33.8 23.4 - 45.4 0.4 03 -0.4 
4 weeks PD3* 71 70 98.6 92.4 -100 199.9 150.9 - 264.7  68 3 4.4 0.9 - 12.4 0.3 0.2 -0.3 
10.5 weeks PD3* 53 52 98.1 89.9 -100 58.8 41.8 - 82.8  61 12 19.7 10.6 - 31.8 0.4 0.3 -0.5 
12 months PD3 65 64 98.5 91.7 - 100 7.3 5.1 - 10.6  64 4 6.3 1.7 - 15.2 0.3 0.2 - 0.3 
Anti-HBs               
Baseline 72 26 36.1 25.1 - 48.3 14.0 9.6 - 20.5  70 29 41.4 29.8 - 53.8 16.6 11.0 - 25.0 
4 weeks PD3* 68 68 100.0 94.7 - 100 10081.6 7304.9 - 13744.4  64 63 98.4 91.6 - 100 392 297.0 - 518.5 
12 months PD3 65 65 100.0 94.5 - 100 2751.1 2182.0 - 3468.6   64 64 100.0 94.4 - 100 264 213.8 - 325.6 
 GMT: Geometric Mean Titers, PD3: Post Dose 3; *Aponte et al[11]  
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Reverse cumulative distribution function for anti-CSP and anti-HBs antibodies GMTs 
immunization groups at one, 3.5 months (except for anti-HBs) and 12 months after dose 3 
are presented in figure 1. The mean concentration of GMTs values for anti-CSP antibodies 
were high at all time points after dose 3 of RTS,S/AS02D immunization. Although a 
decrease in GMTs was observed with time, the levels of anti-CSP GMTs remained far 
above the cut-off point (0.5 U/mL). A small proportion of participants immunized with 
Engerix-B™ showed positive anti-CSP GMTs, especially at 3.5 months after dose 3.  
At all time points, the anti-HBs GMTs were above the seroprotective level (more than 10 
mIU/mL), although the response was higher for the recipients of the RTS,S/AS02D 
vaccine. 
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Figure 1: Reverse cumulative distribution of anti-CSP (left side) and anti-HBs (right side) 
antibodies GMTs after immunization. Plots for four weeks, 10.5 weeks and 12 months 
post-immunization are shown in top, middle and bottom rows respectively. Immunization 
groups are represented by red and black lines (for RTS,S/AS02D and Engerix-B™ 
respectively). Wilcoxon ranksum p-values for comparison of mean GMTs concentrations 
are shown in each plot. 
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Tables 3 and 4 compare the anti-CSP and anti-HBs-specific IFN- and IL-2 CD4+ and 
CD8+ responses between RTS,S/AS02D and Engerix-B™  vaccination groups.  
The baseline-specific levels of IFN- and IL-2 were low and not statistically significant 
between the groups (p>0.05).  The median range of stimulation indices for CD4+ and 
CD8+ T cells varied from 0.81 to 1.34 in both immunization groups.  
 
Participants who received RTS,S/AS02D had a higher median SI of CS-specific IFN-
producing CD8+ T cells and CSP-specific IL-2 producing CD4+ T cells as compared to 
the Engerix-B™  group (Wilcoxon rank sum p-values for IFNγ CD8+ = 0.029 and for IL-
2 CD4+= 0.043) at 10.5 weeks post dose three). In terms of HBs-specific responses, the 
median SI of HBs-specific IL-2 and IFN-producing CD8+ T cells was higher in the 
RTS,S/AS02D group when compared to the Engerix-B™  vaccinated participants 
(Wilcoxon rank sum p-values for IFNγ = 0.015 and for IL2 = 0.030)  at 10.5 weeks post 
immunization.  
The median SI of anti-CS specific IFN-γ producing CD8+ T cells at the same time point 
was 1.13 (IQR: 0.79 - 1.67; p=0.029).  For specific IL-2 producing CD4+ T cells, the 
median SI was 1.14 (IQR: 0.74 – 1.60, p=0.043) at 10.5 weeks post dose three.    
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Table 3: Anti-CS specific IFN- and IL-2 CD4+ and CD8+ responses between 
RTS,S/AS02D and Engerix-B™  vaccination groups. 
Table 3 
       
Anti-CSP antibodies Engerix-B™   RTS,S/AS02D   
  n 
Median 
SI IQR n 
Median 
SI IQR p*  
IFNγ CD4+               
Baseline 62 0.98 0.71 - 1.40 64 1.07 0.72 - 1.56 0.693 
4 weeks post D3 75 1.20 0.77 - 1.61 75 1.16 0.85 - 1.75 0.611 
10.5 weeks post D3 69 1.09 0.85 - 1.47 63 1.18 0.90 - 1.59 0.213 
IFNγ CD8+               
Baseline 62 1.09 0.78 - 1.76 64 1.07 0.70 - 1.73 0.872 
4 weeks post D3 75 1.04 0.67 - 1.57 75 1.04 0.66 - 1.57 0.891 
10.5 weeks post D3 69 1.05 0.67 - 1.41 63 1.25 0.84 - 1.85 0.029 
IL2  CD4+               
Baseline 62 1.00 0.55 - 1.58 64 1.17 0.70 - 1.44 0.762 
4 weeks post D3 69 1.05 0.71 - 1.65 70 1.32 0.95 - 2.00 0.052 
10.5 weeks post D3 68 1.00 0.66 - 1.44 59 1.25 0.92 - 1.74 0.043 
IL2  CD8+               
Baseline 62 1.14 0.74 - 1.82 64 1.37 0.84 - 1.78 0.617 
4 weeks post D3 69 1.04 0.66 - 1.86 70 1.14 0.78 - 1.86 0.626 
10.5 weeks post D3 68 0.86 0.54 - 1.38 59 1.04 0.76 - 1.61 0.086 
*p value: Wilcoxon Rank Sum test 
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Table 4: Anti-HBs specific IFN- and IL-2 CD4+ and CD8+ responses between 
RTS,S/AS02D and Engerix-B™  vaccination groups. 
        
Anti-HBs antibodies Engerix-B™   RTS,S/AS02D   
  n 
Median 
SI IQR n 
Median 
SI IQR p*  
IFNγ CD4+               
Baseline 62 1.04 0.56 - 1.31 64 0.88 0.52 - 1.33 0.503 
4 weeks post D3 75 1.17 0.71 - 1.75 75 1.24 0.76 - 1.67 0.533 
10.5 weeks post D3 69 1.03 0.74 - 1.47 63 1.08 0.77 - 1.59  0.769 
IFNγ CD8+               
Baseline 62 0.86 0.49 - 1.50 64 0.83 0.47 - 1.67 0.970 
4 weeks post D3 75 1.08 0.63 - 1.71 75 1.06 0.74 - 1.70 0.423 
10.5 weeks post D3 69 0.81 0.58 - 1.21 63 1.08 0.68 - 1.49 0.015 
IL2 CD4+               
Baseline 62 0.97 0.58 - 1.32 64 1.14 0.84 - 1.17 0.220 
4 weeks post D3 69 1.19 0.69 - 1.79 70 1.34 0.95 - 1.79 0.185 
10.5 weeks post D3 68 1.04 0.72 - 1.37 59 1.18 0.81 - 1.88 0.065 
IL2  CD8+               
Baseline 62 0.91 0.60 - 1.40 64 1.05 0.60 - 1.51 0.830 
4 weeks post D3 69 1.14 0.62 - 1.67 70 1.16 0.83 - 1.65 0.451 
10.5 weeks post D3 68 0.89 0.52 - 1.26 59 1.28 0.63 - 1.65  0.030 
p* value: Wilcoxon Rank Sum test 
       
 
 
 
 
 
20 
 
 
We found no evidence of association between antibodies anti-CSP and specific cell 
mediated responses (CD4+ SI for IL-2 and CD8+ SI for IFN- (figure 2). 
                   
 
Figure 2: Association between anti-CSP specific cytokine responses (CD4+ IL-2 and 
CD8+ IFN-γ on top and lower panel respectively) and anti-CSP antibodies. Plots for four 
and 10.5 weeks post-immunization are shown at left and right side respectively. CSP-
specific cytokines and antibodies are expressed in log scale and p-values were obtained 
from linear regression models. 
 
 
 
4 weeks  10.5 weeks  
4 weeks  10.5 weeks  
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For the comparison of children in the highest tertile of anticircumsporozoite response 
versus those in the lowest tertile in terms of anti-CS specific CD4+ SI for IL-2 and IFN- 
the reduction in hazard of malaria infection were not statistically significant as shown in 
table 5. These responses were only evaluated for specific CD4+ SI for IL-2 and CD8+ SI for 
IFN- that previously was statistically significant (tables 3 and 4). When the analyses were 
adjusted by gender, no statistical significant differences were noted (data not shown).   
 
 
 
Table 5: Association between anti-CSP CMI responses and the risk of malaria infection 
Stimulation indices     Time At Incidence Reduction      
 Anti-CS  Tertiles  Episodes  Risk (Episodes per in Hazard (95% CI) p* 
      (PYAR) PYAR) (1-HR)%     
IL-2  CD4+ (4 weeks PD3) 
Lower  4 5.59 0.72 
18.30% (-267.9; 81.8) 0.793 
Higher  3 5.57 0.54 
IL-2 CD4+ (10.5 weeks PD3) 
Lower  5 4.23 1.18 
-12.00% (-295.3; 68.2) 0.86 
Higher  5 4.36 1.15 
IFNγ CD8+ (4 weeks PD3) 
Lower  3 5.23 0.57 
-103.60% (-690.9; 47.6) 0.305 
Higher  7 5.78 1.21 
IFNγ CD8+ (10.5 weeks PD3) 
Lower  8 5.15 1.55 
48.80% (-97.0; 86.7) 0.33 
Higher  3 4.54 0.66 
*p-value from Cox regression model using Wald test; 
PD3: post Dose 3   
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Limitations of the study 
 
The cell mediated immune response was measured at four and  10.5 weeks after the third 
doses of RTS,S/AS02D or Engerix™ immunization, periods that do not coincide 
necessarily with the times were these responses can reach optimally high titers (before four 
and 10.5 months).  Data on malaria incidence was derived from the primary efficacy study 
[11]. 
Cell-mediated immunity data presented here is only related to intracellular cytokine 
staining of CD4+ and CD8+ lymphocytes. Data pertaining cytokine measures in 
supernatants were not included in this analysis.  
 
The sample size was estimated to evaluate safety and humoral immunogenicity as well as 
the proof-of-concept of efficacy. The process to obtain the CMI is complex, mainly due to a 
high volume of blood required and long and complex procedures, thus leading to a 
considerable amount of missing data that further reduced the power to detect differences.  
For the same reason, i.e. incomplete data related to CMI, multivariate analysis on the 
relationship between humoral and CMI responses as well as its association with the risk of 
malaria led to inconclusive findings and were excluded from this report. 
There is no power calculation to estimate the effect between the immune response and the 
risk of malaria. We did not adjust the p-values for the multiple comparisons. So the p-value 
limit of 0.05 has been considered as indicating statistical significance. 
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CHAPTER FOUR: DISCUSSION 
 
Previous studies with GSK Biologicals candidate malaria vaccine RTS,S/AS02D in 
Mozambique, Kenya and Tanzania showed that vaccination of infants  (less than one year 
of age)  confers protection against infection and clinical malaria endemic areas [11, 16, 17]. 
Over a period of 12 months, RTS,S/AS02D was shown to be immunogenic in Mozambican 
infants, inducing in the RTS,S/AS02D group high GMTs anti-CSP antibody levels after 
three doses, despite indication of waning over time (especially from 10.5 to 12 months after 
dose three). This indicates that anti-CSP antibodies, probably together with other cellular 
immune responses, may be involved in the initial protection against malaria in infants 
vaccinated with the RTS,S vaccine.  
 
The RTS,S vaccine is being developed as a conjugate vaccine to protect children against 
malaria and hepatitis B. Data from the evaluation of cellular mediated responses to both 
the P. falciparum circumsporozoite protein and hepatitis B surface antigen shows that the 
RTS,S/AS02D vaccine was immunogenic in infants eliciting levels of detectable cellular 
immune responses to both CS and HBs antigens following immunization.  
 
Increased secreted levels of IFN and IL-2 to both antigen vaccine components were 
observed by intracellular cytokine staining up to 10.5 weeks after immunization.  HBS-
specific IFN- and IL-2 responses were more frequently induced by the RTS,S/AS02D 
vaccine than by the control Hepatitis-B vaccine, possibly due to a stronger Th1 adjuvant 
effect of AS02D compared with alum present in the Engerix-B™ Hepatitis B vaccine. 
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Although RTS,S/AS02D immunization has induced CSP-specific cellular immune 
responses detected by intracellular cytokine staining that are statistically significant when 
compared to the Hepatitis-B group or pre-immune responses, the percentage of positive 
cells was very low and the biological significance cannot be assured. 
 
The median stimulation indices for CSP-induced responses were approximately 0.25 higher 
in the RTS,S/AS02D group than in the control Engerix-BTM vaccine group, when taking in 
consideration only the observed statistical significant differences between these groups. 
Making approximations, this could be translated to around 0.08 and 0.09% increment in the 
CSP-specific CD4+ and CD8+ T cell population in children immunized with RTS,S. 
 
We found no association between CSP-specific T cell immune responses to RTS,S vaccine  
and the risk of malaria infection. However, a potential limitation of the ICS assay 
performed was the use of whole blood instead of peripheral blood mononuclear cells 
(PBMC), due to the small volumes of blood available for the assays. Whole blood assays 
may give more background in ICS than PBMC thus weakening the signal to noise ratio for 
the antigen-specific response. The true differences between the immunization groups may 
thus be greater than detected in this study.  
 
The current analysis is an initial description of CSP-specific T cell immune responses 
elicited in infants immunized with RTS,S vaccine. The identification of correlates of the 
RTS,S vaccine protection constitutes a goal still to be achieved, hence further investigation 
is needed.  The role of cytokine-producing T cells has been under intense study in efforts to 
identify correlates of malaria vaccine efficacy. However, there is a wealth of possible 
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complications mainly due to the use of different assays to measure antigen-specific T cell 
activity and the lack of functional assays. The RTS,S vaccine candidate has been shown to 
elicit cellular immune responses by various techniques in the past [5, 8, 26, 27], but it is 
still unclear how these cellular responses correlate with vaccine protection.  
 
The next steps in the development of this vaccine candidate are the phase III trials in 
preparation for the next 3-4 years.  It has been suggested that IFN- T-cell responses to 
natural malaria exposure are infrequent in children [5, 11] and it is hypothesized that 
repeated exposure and a mature immune system may be required. Thus a lot of 
opportunities to better understand and identify how this vaccine acts to elicit immunity are 
to be considered and have to be included in upcoming trials to accelerate further 
development of malaria vaccines.  
Despite having found weak CSP-specific T cell responses induced by the RTS,S/AS02D 
immunization, the results indicate that specific cell-mediated immunity can be elicited in 
infants less than one year of age. 
Hopefully, with a successful completion of these plans, a first generation of malaria vaccine 
would be available to protect African infants in the near future.    
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CHAPTER FIVE: CONCLUSIONS AND RECOMMENDATIONS 
 
In conclusion, we found that the RTS,S/AS02D vaccine has induced seropositivity rates for 
anti-CSP antibodies and seroprotection rates for anti-HBs antibodies that were detectable 
after 12 months following vaccination with RTS,S/AS02D in staggered co-administration 
with TETRActHib. The anti-HBs responses were higher in recipients of RTS,S/AS02D 
than of Hepatitis B control vaccine. 
The analysis also demonstrated that this vaccine elicits detectable levels of cytokines CSP-
specific cell mediated responses (namely CD4+ and CD8+ producing IL-2 and IFN-γ). 
However, no evidence of association was found either between anti-CSP antibodies and 
specific cell-mediated responses; or between the former one and the risk of malaria in this 
group of infants immunized with the RTS,S/AS02D vaccine.  
 
In the light of the above-mentioned, our first recommendation is the continuity of further 
research of the type and specificity of immune responses against CSP during phase III 
studies of this vaccine candidate. 
Secondly, we recommend the optimization of ICS assays using total whole blood to be used 
in African infants due to the less amount of blood required for this assay and fewer ethical 
concerns (contrary for example to ICS assays in peripheral blood mononuclear cells, 
technique already optimized for adults but not infants).  
Finally, evaluation of cost-effectiveness of this intervention as well as its expected 
integration in the EPI schedules are recommended to be included in the next phase III 
studies. 
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